Clinical Utility of in-vivo MRS Measurements of 2-Hydroxyglutarate in IDH-Mutated Gliomas

Changho Choi¹, Sandeep Ganji², Akshay Madan¹, Ralph DeBerardinis¹, Bruce Mickey¹, Craig R. Malloy¹, Robert Bachoo¹, Elizabeth A. Maher¹

Following the finding of the production of 2-hydroxyglutarate (2HG) in IDH-mutated gliomas, several researchers reported in-vivo detection of this onco-metabolite by 1H-MRS. Although the role of 2HG associated with IDH mutation is well established for prognosis, how it can be used for improving the patient care is largely unknown. In this paper, using 2HG data from 30 patients obtained over time, we demonstrate that 2HG is a remarkably sensitive biomarker for monitoring the tumor growth/progression and response to treatment in patients.